Development of Peptide-Based Personalized Cancer Vaccines
Jesse Z. Dong
Vice President, Peptide Chemistry, Neon Therapeutics
Neon Therapeutics is pursuing an exciting clinical development program of a personalized neoantigen vaccine. Neoantigens arise as a result of somatic mutations during the development and progression of tumors. They are inherently non-self and are seen as foreign by the immune system. Mounting evidence suggests that immune rejection of tumors, for example which is seen with checkpoint modulators, may be mediated by recognition of neoantigens. Neon’s peptide vaccine targets neoantigens unlocking the immune system to attack tumors.